Figure 1.

Serum fasting glucose, lipid, SGOT and SGPT concentrations in the Empa and control groups after five weeks of empagliflozin/vehicle oral administration. (a). A significant reduction in fasting blood glucose, total cholesterol, triglyceride levels was observed in the Empa group at the end of the treatment period compared to baseline. Fasting glucose was the only significantly increased parameter in the control group at the end of intervention as compared to baseline values. (b). Significant changes were detected from baseline in triglyceride/HDL ratio between two groups. (c). Serum SGOT and SGPT levels were reduced in Empa group as compared to Control group (p = 0.07 and p = 0.048, respectively) (n = 8 per group). Data are shown as the mean ± SD (***: p < 0.001; **: p < 0.01, *: p < 0.05).